sucroferric oxyhydroxide + digoxin

**Sucroferric oxyhydroxide** (PA21) is an iron-based, non-calcium, non-aluminum phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. **Digoxin** is a cardiac glycoside used for heart failure and certain arrhythmias. This listing refers to the co-administration or combination of both drugs, not a fixed-dose combination. Mechanistically, sucroferric oxyhydroxide acts by binding phosphate in the gastrointestinal tract and preventing its absorption, while digoxin inhibits the sodium-potassium ATPase in cardiac myocytes, increasing intracellular calcium and myocardial contractility. Both drugs may potentially interact, primarily via altered absorption or binding interactions, but there is no evidence of a unique, approved fixed combination product.

Brand names

Velphoro + digoxin

Other names

sucroferric oxyhydroxide + digoxin